Elsevier Launches New Open Access Journal: Molecular Metabolism
MUNICH, January 28, 2013 /PRNewswire/ --
Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce the launch of Molecular Metabolism in affiliation with the German Research Center for Environmental Health (Helmholtz Zentrum München, Munich, Germany) and the German Center for Diabetes Research (DZD, Germany). Molecular Metabolism is a new, open access journal devoted to the rapid publication of breakthroughs in mechanistic metabolism research.
Metabolic diseases including obesity, diabetes and related co-morbidities remain on the rise. Impaired cellular metabolism is emerging as an etiological factor for an increasing number of illnesses, such as cancer, cardiovascular diseases or neurodegenerative disorders. Molecular Metabolism aims to publish hypothesis-driven research from leading scientists, thus paving the way to a better understanding of metabolic physiology, and enabling progress toward the development of personalized medicines for preventing and curing these metabolism-related diseases.
Matthias Tschöp (Helmholtz Zentrum München and Technische Universität München) founded the journal together with Jens Brüning (University of Cologne), Tamas Horvath (Yale University), and Martin Myers (University of Michigan). Their vision for Molecular Metabolism is an open access journal with a fast track publication process aiming for peer review-based decisions within one week. Molecular Metabolism will be able to offer online publication of accepted manuscripts within 14 days of submission in order to be able to disseminate breakthrough discoveries in mechanistic and translational metabolism research with unprecedented speed.
"Translational research is an integral part of the research approach for investigators around the world. It enables the transformation of knowledge into medical progress and the realization of the translational potential of basic research findings for medical applications," said Matthias Tschöp. "Molecular Metabolism has been launched to provide a home for translational metabolic disease research, and we welcome submissions from all metabolism researchers."
Articles published in Molecular Metabolism are freely available to anyone and are published online on ScienceDirect.
For more information or to submit an article, go to Molecular Metabolism.
About Helmholtz Zentrum München
Helmholtz Zentrum München is the German Research Center for Environmental Health. It investigates important common diseases, which develop from the interaction of lifestyle, environmental factors and personal genetic background, focusing particularly on diabetes mellitus and chronic lung diseases. The Helmholtz Zentrum München has about 2,000 staff members and is headquartered in Neuherberg, in the north of Munich. Helmholtz Zentrum München is a research institution of the Federal Republic of Germany and the Free State of Bavaria. It is a member of the Helmholtz Association of German Research Centers, a community of 18 scientific-technical and medical-biological research centers with a total of about 34,000 staff members.
About German Center for Diabetes Research (DZD)
The German Center for Diabetes Research (DZD) is a national network comprised of experts in the field of diabetes research that connects basic research, epidemiology and clinical applications. Members of the network are Helmholtz Zentrum München, the German Diabetes Center in Düsseldorf, the German Institute for Human Nutrition in Potsdam-Rehbrücke, Paul Langerhans Institute of the Carl Gustav Carus University Hospital in Dresden and the Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Zentrum München at the University of Tübingen. The goal of the DZD is to find answers to unsolved questions in diabetes research via an innovative, integrative research approach and to make a major contribution to improving the prevention, diagnosis, and therapy of diabetes mellitus (http://www.dzd-ev.de/en)
Open Access Publishing at Elsevier
Elsevier has been providing open access publishing options since 2005. Today, researchers can choose to publish in over 1,500 hybrid journals as well as more than 30 full open access journals and these numbers will continue to grow rapidly. All of Elsevier's open access publications have been peer reviewed, ensuring that the broader community not only reads the latest research but that it is factual, original and of the highest quality and ethical standards. For more information about Elsevier's open access program, visit http://www.elsevier.com/openaccess
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Mer från detta företag
Skapa innehåll för din webbplats
Förbättra din webbplats eller blogg med PR Newswires skräddarsydda nyhetsflöden.
Kontakta PR Newswire
Skicka oss ett mail till firstname.lastname@example.org eller ring oss på +46 (0)739 44 89 87 eller +46 (0)739 44 36 18
Bli en PR Newswire kund
Begär mer information , se PR Newswire produkter & tjänster eller ring oss på +46 (0)739 44 89 87 eller +46 (0)739 44 36 18